Boston QSP November Event Announcement: Quantitative and Systems Pharmacology Driving Early Drug Dev
Boston QSP November Event: Quantitative and Systems Pharmacology Driving Early Drug Development
Boston QSP is excited to announce Dr. Birgit Schoeberl from Merrimack Pharmaceuticals, Inc. as the guest speaker at our November event. She leads early stage drug discovery and development as the head of Discovery at Merrimack. This event will be held at Havana Room, 5th Floor, Cambridge Innovation
Center, 1 Broadway, Cambridge MA. Click here for RSVP and more info.
Please join us to share your experiences, network with people from diverse disciplines, and learn from Birgit about the crucial role that QSP approach played in the development of Seribantumab (MM-121) from early discovery to early clinical testing. MM-121 is a fully human monoclonal antibody that targets the HER3 receptor. It is currently being tested in combination with docetaxel and pemetrexed in phase 2 study of non-small cell lung cancer patients. Only patients who are heregulin positive based on Merrimack's pre-identified biomarker profile are enrolled for the study.
Remember to register for this free event here. RSVP is required for a guaranteed participation.
(Photo: September Boston QSP event. )